Dr. Erik D Roberson's lab at the University of Alabama at Birmingham focuses on understanding how disruptions in circadian rhythms affect brain function in relation to Alzheimer's disease. They investigate how changes in neuronal excitability, particularly in certain inhibitory neurons, may contribute to the disease's early stages. Through innovative techniques, the lab aims to uncover mechanisms linking circadian biology with cognitive impairment and develop potential therapeutic strategies.

Dr. Jeremy H. Herskowitz runs a research lab focused on understanding how some individuals can maintain cognitive function despite having Alzheimer's disease pathology in their brains. The lab aims to identify the molecular and cellular mechanisms that contribute to this resilience and discover potential therapeutic targets for delaying or preventing dementia. By studying brain regions and synaptic health, they hope to pave the way for new treatments that improve cognitive function in older adults at risk for Alzheimer's disease.

Dr. Jeremy J. Day's lab studies how substances like cocaine affect the brain, particularly in regions linked to reward and motivation. They focus on understanding the roles of specific proteins, Gadd45b and Reelin, in altering gene expression and behavior when exposed to drugs. By exploring these molecular mechanisms, the lab aims to uncover new therapeutic targets for addiction treatment and enhance our understanding of motivated behavior disorders.

Dr. Peter H. King’s lab focuses on understanding and potentially treating inflammation caused by ischemic strokes, which are a significant cause of death and disability. The team investigates a molecule called HuR that plays a role in promoting inflammation in the brain after a stroke. By inhibiting HuR, they aim to reduce inflammation and enhance neuroprotection to improve recovery outcomes for stroke patients, ultimately contributing to better management of strokes and related neurological diseases.

Dr. Bryan W. Luikart's lab at the University of Alabama at Birmingham focuses on understanding the role of the PTEN gene in neuron development and its implications for autism spectrum disorders (ASD). By studying how PTEN dysfunction affects neuronal growth and synaptic connections, the research aims to uncover potential new treatment approaches for ASD. The lab employs innovative genetic techniques to explore these crucial aspects of neurobiology that influence cognitive and emotional functions.

Dr. Jamie Peters' lab focuses on developing new treatments for opioid use disorder, a serious addiction problem. They are studying a novel compound called tabernanthalog, which helps reduce drug-seeking behavior without the side effects seen in similar drugs. The lab investigates how this compound works in the brain to promote healing and reduce relapse in addiction.

Dr. Nita A Limdi's lab focuses on improving healthcare through genomic medicine by implementing population genomic screening and a regional eConsult service to help identify genetic risks in patients. The lab seeks to integrate genomic testing into primary care, enabling better diagnosis and treatment of preventable conditions. By collaborating with community stakeholders, they aim to empower healthcare providers and improve patient outcomes across the Southeast region of the U.S.

Dr. Jerzy Szaflarski's lab at the University of Alabama at Birmingham specializes in understanding how neuroinflammation relates to temporal lobe epilepsy using advanced imaging techniques. The lab focuses on a new method known as magnetic resonance spectroscopic imaging and thermometry (MRSI-t) to visualize brain temperature changes, which can indicate underlying inflammation. By studying these processes, the lab aims to improve diagnosis and treatment strategies for individuals with epilepsy.

Dr. Laura A. Volpicelli-Daley's lab at the University of Alabama at Birmingham focuses on understanding the cognitive impairments associated with Lewy body dementias, such as Parkinson's Disease Dementia and Dementia with Lewy Bodies. The research investigates how genetic mutations in the GBA1 gene and lipid metabolites like glucosylsphingosine contribute to cognitive decline and aims to identify new therapeutic strategies. By using mouse models and brain tissue analysis, the lab explores the molecular mechanisms underlying these neurodegenerative diseases and their effects on brain function.

Dr. Craig M Powell's lab at the University of Alabama at Birmingham focuses on understanding the genetic causes of neurodevelopmental disorders like autism and intellectual disability. They use mouse models to investigate specific genes and their effects on brain function and behavior. By combining advanced techniques like RNA sequencing and MRI, the lab aims to identify potential therapies for these conditions in the future.